and financials report provides comprehensive understanding and unprecedented access to the gynecology partnering deals and agreements entered into by the worlds leading healthcare companiesRead the full report: http://www.reportlinker.com/p03021529-summary/view-report.htmlDescriptionGlobal

Gynecology Partnering 2010-2017: Deal trends, players and financials provides the full collection of Gynecology disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Gynecology partnering deals Financial deal terms for headline, upfront and royalty by stage of development Gynecology partnering agreement structure Gynecology partnering contract documents Top Gynecology deals by value Most active Gynecology dealmakers Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. The report takes readers through the comprehensive Gynecology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gynecology deals. The report presents financial deal terms values for Gynecology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. The initial chapters of this report provide an orientation of Gynecology dealmaking trends. Chapter 1 provides an introduction to the report. Chapter 2 provides an overview of the trends in Gynecology dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication. Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates. Chapter 4 provides a review of the leading Gynecology deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gynecology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides comprehensive access to Gynecology deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive directory of all Gynecology partnering deals by specific Gynecology target announced since 2010. The chapter is organized by specific Gynecology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. In addition, a comprehensive appendix is provided with each report of all Gynecology partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Gynecology partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gynecology technologies and products. Report scope
Global Gynecology Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Gynecology trends and structure of deals entered into by leading companies worldwide. Global Gynecology Partnering 2010 to 2017 includes:
Trends in Gynecology dealmaking in the biopharma industry since 2010 Analysis of Gynecology deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Gynecology deal contract documents Comprehensive access to over 3500 Gynecology deal records The leading Gynecology deals by value since 2010 Most active Gynecology dealmakers since 2010 The report includes deals for the following indications: Adenomyosis, Cervical Intraepithelial Neoplasia (CIN), Endometriosis, Fibroids, Human papillomavirus (HPV), Infertility, Menopause, Ovarian failure, Pelvic inflammatory disease, Polycystic ovary syndrome, Pre-menstrual syndrome, Prolapse, Amenorrhea, Dysmenorrhea, Pelvic pai, Vaginitis, plus other gynecological indications. In Global Gynecology Partnering 2010 to 2017, available deals and contracts are listed by:
Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Gynecology Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 200 gynecology deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are the sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Read the full report: http://www.reportlinker.com/p03021529-summary/view-report.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-gynecology-partnering-2010-2017-deal-trends-players-and-financials-300421676.html

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.

Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished.Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.Full Disclaimer